The FDA database recorded a supplement dated 25 August 2026 to abbreviated new drug application ANDA208934, Sun Pharma's generic tadalafil.
The record does not state what the supplement changed. Supplements to generic applications usually cover manufacturing, labelling alignment with the reference product, or packaging, and are administrative rather than safety actions. There is no indication of a new indication, a safety communication or a recall.
Tadalafil is widely prescribed for erectile dysfunction and lower urinary tract symptoms. No action is needed by prescribers on the basis of this entry.
- No change to prescribing is indicated by this record
- Continue to check nitrate use and cardiovascular status before prescribing tadalafil
- Watch for any accompanying FDA safety communication, of which there is none at present
Why it matters
Regulatory entries for widely used generics can look like news; this one does not change practice.
Don't overread it
A supplement to a generic application is administrative — it is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free